Xenotransplantation for liver therapy or: Can porcine hepatocytes generate physiological functions sufficient for a human patient in ALF?

International Journal of Artificial Organs

Volumn 25, Issue 10, 2002, Pages 1019-1028

  Hammer, Claus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Hepatocytes; Liver; Physiology; Xenotransplantation

Indexed keywords

ARTIFICIAL ORGANS; CELL CULTURE; CELL ENGINEERING; PATIENT TREATMENT; PHYSIOLOGY; TISSUE; TISSUE ENGINEERING;

ARTIFICIAL LIVER; CULTURE CONDITIONS; HEPATOCYTES; HUMAN HEPATOCYTES; HUMAN PATIENTS; LIVER DEVICES; PHYSIOLOGICAL FUNCTIONS; PHYSIOLOGICAL INTERACTIONS; TISSUES ENGINEERINGS; XENOTRANSPLANTATION;

CELLS;

ACUTE PHASE PROTEIN; ALBUMIN; BILE ACID; BILE SALT; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CALCITONIN; CELL ADHESION MOLECULE; CHENODEOXYCHOLIC ACID; COMPLEMENT; CYTOKINE; DEOXYCHOLIC ACID; DIAZEPAM; ENZYME; ERYTHROPOIETIN; GLYCINE; GROWTH FACTOR; HYODEOXYCHOLIC ACID; INSULIN; INTERFERON; LIPID; NAFAMSTAT MESILATE; PROSTAGLANDIN; PROTEIN; TAURINE; THROMBOPLASTIN; URSODEOXYCHOLIC ACID;

APHERESIS; ARTIFICIAL LIVER; BILE ACID METABOLISM; BIOCHEMISTRY; BIOCOMPATIBILITY; CELL CULTURE; CLINICAL PRACTICE; CRYOPRESERVATION; DEVICE; DRUG DETOXIFICATION; DRUG EFFECT; ENZYME RELEASE; HEPATIC COMA; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOMODULATION; LIPID METABOLISM; LIVER; LIVER CELL; LIVER FAILURE; LIVER PERFUSION; LIVER TRANSPLANTATION; NONHUMAN; PHYSIOLOGY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECIPIENT; REVIEW; SPECIES DIFFERENCE; SWINE; THROMBOCYTE AGGREGATION INHIBITION; TISSUE ENGINEERING; XENOGRAFT; XENOTRANSPLANTATION;

EID: 0036816635     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880202501018     Document Type: Review

References (51)

1. Chamuleau R. Liver and artificial liver. Ned-Tidschr-Geneesek 1998; 142: 1300-5.
2. Bain V, Montero J, De La Mata M. Can J Gastroenterol 2001; 15: 313-318.
3. Nyberg S, Misra S. Hepatocyte liver assist system a clinical update. Mayo Clin Proc 1998; 73: 765-71.
4. Wang L, Sun J, Li L, et al. Comparison of porcine hepatocytes with human immortalized human hepatoma cells for use in a bioartificial liver support system. Cell Transplant 1998; 7: 49-68.
5. Hughes R, Williams R. Use of bioartificial and artificial liver support devices. Semin Liver Dis 1996; 16: 435-44.
6. Nyberg S, Hibbs J, Hardin J, et al. Influence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes. Liver Transpl 2000; 6: 76-84.
7. Donato M, Castell J, Gomez-Lechon M. Characterisation of drug metabolizing activities in pig hepatocytes for use in bioartificial liver: Comparison with other hepatic models. J Hepatol 1999; 31: 542-9.
8. Ellis A, Hughes R, Wendon J, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446-51.
9. Giles G, Boehmig HJ, Anemiya H, Halgrimson C, Starzl TE. Clinical heterotransplantation of the liver. Transplant Proc 1970; 2: 506-12.
10. Marino M, Doyle B, Nour B, Starzl TE. Baboon liver transplantation in humans: Clinical experience and principles learned. In: Xenotransplantation 2nd ed. Cooper DK, Kemp, E, Platt JL, White D, eds. Berlin; Springer Verlag, 1997.
11. Calne R, Davis D, Pena J, et al. Hepatic allografts and xenografts in primates. Lancet 1970; 103-6.
12. Calne R, White H, Herberton B, et al. Pig-to-baboon liver xenografts. Lancet 1968; 1176-8.
13. Jerusalem C, Heyde M, Reinking J, et al. Rejection phenomena in heterotopic liver homo- and heterografts. Transplant Proc 1971; 3: 554-7.
14. Pöhlein C, Pascher A, Storck M, et al. The function of transgenic human DAF expressing porcine livers during hemoperfusion with human blood. Transpl Int 1996; 9: 392-6.
15. Pascher A, Pöhlein C, Stangl M, et al. Application of immunoapheresis for delaying hyper acute rejection during isolated xenogeneic pigliver perfusion. Transplantation 1997; 63: 867-75.
16. Seehofer D, Baatz H, Thiery J, Hammer C. Quantitative analysis of the microcirculation of xenogeneic hemoperfused rat livers by intravital microscopy. Transpl Int 1996; 9 (suppl. 1) S9-99.
17. Seehofer D, Baatz H, Thiery J. et al. Fluorescence video-microscopic assessment of xenogeneic microcirculation and impact of antibody removal by immuno-absorption. Transplantation 1997; 63: 460-5.
18. Cameron D, Burger H, Catt K, et al. Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in isolated perfused pig liver. Metabolism 1972; 21: 895-904.
19. Kwekkeboom J, Rpincen H, Voohuizen M, et al. Comparison of taurocholate accumulation in hepatocytes of pig, rat and man. Biochem Biophys Res Commun 1989; 162: 619-25.
20. Lesca P, Witkamp R, Maurel P, Galtier P. The pig as a model for studying AH receptor and other PAH-binding proteins in man. Biochem Biophys Res Commun 1994; 200: 475-81.
21. Keiding S, Johansen S, Midtboll I, et al. Ethanol elimination kinetics in human liver and pig liver in vivo. Am Physiol Soc 1979; 237: E316-24.
22. Gerlach J, Schnoy M, Smith M, et al. Hepatocyte culture between woven capillary network - A microscopy study. Artif Organs 1994; 18: 1-5.
23. Naik S, Trenkler D, Santangini H, et al. Isolation and culture of porcine hepatocytes for artificial liver support. Cell Transplant 1995; 5: 107-15.
24. Hammer C. Physiological obstacles after xenotransplantation. Ann NY Acad Sci 1998; 862; 19-27.
25. Takahashi M, Ishikura H, Takahashi C, et al. Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum. ASAIO J 1993; 39: M242-6.
26. Joly A, Desjardins J, Fremond B, et al. Survival, proliferation, and functions of porcine hepatocytes encapsulated in coated alginate beads: A step toward a reliable bioartificial liver. Transplantation 1997; 63: 795-803.
27. Baquerizo A, Mhoyan A, Kearns-Jonker M, et al. Characterisation of human xeno reactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment. An ex-vivo model of pig to human xenotransplantation. Transplantation 1999; 67: 5-18.
28. De-Bartolo L, Von Schweder G, Haverich A, Bader A. A novel full scale flat membrane bioreactor utilizing porcine hepatocytes: Cell viability and tissue-specific function. Biotechnol Prog 2000; 16: 102-8.
29. Eguchi S, Kawazoe Y, Sugiyama N, et al. Effects of recombinant human hepatocyte growth factor on the proliferation and function of porcine hepatocytes. ASAIO J 2000; 46: 56-9.
30. Hammer C, Linke R, Wagner F, Diefenbeck M. Organs from animals for man. Allerg Immunol 1998; 116: 5-21.
31. Starzl T, Fung J, Tzakis A, et al. Baboon to human liver transplantation. Lancet 1993; 341: 65-71.
32. Ramirez P, Chavez R, Majado M, et al. Life supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the non-human primate for up to 8 days. Transplantation 2000; 70: 989-98.
33. Kornberg A, Dietz O, Mau H, et al. Impact of immuno-absorption on xenogeneic extracorporeal pig liver perfusion: Assessment of organ function during autologous reperfusion. Xenotransplantation 1999; 6: 187-93.
34. Collins B, Chiari R, Magee J, et al. Immunopathology of the porcine liver perfused blood of humans of humans with hepatic failure. Transplant Proc 1995; 27: 280-1.
35. Sarich V, Wilson A. Rates of albumin evolution in primates. Proc Natl Acad Sci USA 1967; 58: 142-7.
36. Ramirez P, Munitiz V, Chavez M, et al. Changes in the protein and lipid profile after liver xenotransplantation from pig to baboon. Xenotransplantation 2001; 8: (suppl.) S73.
37. Gregory P, Conolly C, Toner M, Sullivan S. In vitro characterisation of porcine hepatocyte function. Cell Transplant 2000; 9: 1-10.
38. Adham M, Ducerf C, Vernet M, et al. Changes in serum proteins during isolated pig liver perfusion. Transplant Proc 1997; 29: 3015.
39. Mollevi D, Jaurrieta E, Ribas Y, et al. Liver xenotransplantation: Changes in lipid and lipoprotein concentration after long term graft survival. J Hepatol 2000; 32: 655-60.
40. Cozzi E, Tucker A, Langford G, et al. Characterisation of pigs transgenic for human decay accelerating factor. Transplantation 1997; 64: 1383-92.
41. Alwayn I, Robson S. Understanding and preventing the coagulation disorders associated with xenograft rejection. Graft 2000; 4: 50-3.
42. Kawazoe Y, Eguchi S, Sugiyama N, et al. Protective effect of nafamostat mesilate on injury of porcine hepatocytes by human plasma. Cell Transplant 1999; 8: 419-22.
43. Shankar T, Drake S, Solomon S. Insulin resistance and delayed clearance of peptide hormones in cirrhotic rat liver. Am J Physiol 1987; 252: E772-7.
44. Tector A, Berho M, Fridell J, et al. Rejection of pig liver xenografts in patients with liver failure: Implications for xenotransplantation. Liver Transpl 2001; 7: 82-8.
45. Sacca L, Orofino G, Petrone A, Vigorito C. Direct assessment of splanchnic uptake and metabolic effect of human and porcine insulin. J Clin Endocrinol Metab 1984; 59: 191-6.
46. Polonsky K, Jaspan J, Emmanouel D, et al. Difference in the hepatic and renal extraction of insulin and glucagon in the dog. Acta Endocrinol 1983; 102: 420-7.
47. Baker B, Morrow A, Vergalla J, et al. Gamma-aminobutyric acid (GAB AA) receptor function in a rat model of hepatic encephalopathy. Metab Brain Dis 1990; 5: 185-93.
48. De Bartolo L, Bader A. Review of a flat membrane bioreactor as a bioartificial liver. Ann Transplant 2001; 6: 40-8.
49. Sosef N, Abrahamse L, Kerkhove M, et al. Assessment of the AMC-bioartificial liver in the anhepatic pig. Transplantation 2002; 73: 204-9.
50. Koebe H, Danhardt C, Muller-Hocker J, et al. Cryopreservation of porcine hepatocyte cultures. Cryobiology 1996; 33: 127-41.
51. Koebe H, Muhling B, Deglmann C, Schildberg F. Cryopreserved porcine hepatocyte cultures. Chem Biol Interact 1999; 121: 99-115.